Tebao Biotech announced that the 22nd meeting of the 9th board of directors of the company reviewed and passed the relevant bill to clarify the plan to issue convertible corporate bonds to unspecified targets. It is proposed to issue convertible bonds to raise capital of 1,533 billion yuan for a period of 6 years. From July 28, 2026 to July 27, 2032, the initial conversion price is 58.56 yuan/share. Priority placement is given to the original shareholders, and the balance is sold online. In addition, the board of directors also agreed to apply for the listing of convertible bonds on the Science and Technology Innovation Board, open a special account to raise funds, and sign a supervisory agreement.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.